Characterization of transfusion-derived iron deposition in childhood cancer survivors

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1913-1919

  Ruccione, Kathleen S ^a,b,c,f,h   Wood, John C ^d,e,f,h   Sposto, Richard ^b,c,f,g,h   Malvar, Jemily ^b   Chen, Cheng ^h   Freyer, David R ^a,b,c,f,h  

^a LIFE Cancer Survivorship and Transition Program   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c Lynn Cancer Institute   (United States)

^d Divisions of Pediatric Cardiology   (United States)

^e Divisions of Radiology   (United States)

^f Oklahoma City   (United States)

^g University Occupational Health Service and Departments of Preventive Medicine   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; EWING SARCOMA; FEMALE; FOLLOW UP; GENE MUTATION; GERM CELL TUMOR; GROUPS BY AGE; HEART; HEMOCHROMATOSIS; HIGH RISK PATIENT; HUMAN; IRON OVERLOAD; IRON STORAGE; LABORATORY TEST; LIVER; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NASOPHARYNX CARCINOMA; NEPHROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PANCREAS; PREDICTIVE VALUE; RHABDOMYOSARCOMA; RISK ASSESSMENT; SOLID TUMOR; TISSUE LEVEL; ADVERSE EFFECTS; BLOOD; HEART MUSCLE; INFANT; METABOLISM; NEOPLASMS; PROCEDURES; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; INFANT; IRON; IRON OVERLOAD; LIVER; MALE; MYOCARDIUM; NEOPLASMS; PANCREAS; SURVIVORS; YOUNG ADULT;

EID: 84907164375     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0292     Document Type: Article

References (37)

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. (editors). SEER cancer statistics review, 1975-2005, based on November 2007 SEER data submission. Bethesda, MD: National Cancer Institute; 2008.
2. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88: 7-15.
3. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364: 146-56.
4. Blair AB, Tarango C, Bowers D, Leavey P, Journeycake J. Transfusional iron overload in acute lymphoblastic leukemia. San Diego, CA: American Society of Pediatric Hematology Oncology; 2009. p. 707.
5. Eng J, Fish JD. Insidious iron burden in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56: 368-71.
6. Gurram MK, Newman W, Kobrinsky N. Prevalence of iron overload in pediatric oncology patients after blood transfusion. Clin Adv Hematol Oncol 2012; 10: 363-5.
7. Halonen P, Mattila J, Suominen P, Ruuska T, Salo MK, Makipernaa A. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. Pediatrics 2003; 111: 91-6.
8. Jaffer A, Barty R, Jamula E, Wang G, Liu Y, Heddle N, et al. Are children with cancer receiving myelosuppressive therapy at risk for transfusionrelated iron overload? Blood (ASH Annual Meeting Abstracts) 2012; 120: 1180.
9. Jastaniah W, Harmatz P, Pakbaz Z, Fischer R, Vichinsky E, Walters MC. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer 2008; 50: 319-24.
10. Lutz K, von Komorowski G, Durken M, Engelhardt R, Dinter DJ. Myocardial iron overload in transfusion-dependent pediatric patients with acute leukemia. Pediatr Blood Cancer 2008; 51: 691-3.
11. Nelson SC, Bendel AE, Perkins JL. Transfusional Iron Overload in Pediatric Oncology. American Society of Pediatric Hematology/Oncology Abstracts. Toronto, Canada: Pediatric Blood and Cancer; 2007. p. 607.
12. Nottage K, Gurney JG, Smeltzer M, Castellanos M, Hudson MM, Hankins JS. Trends in transfusion burden among long-term survivors of childhood hematological malignancies. Leuk Lymphoma 2012; 54: 1719-23.
13. Reddy K, Eng J, Carlson C, Ginsberg J, Fish J. Impact of transfusional support for childhood cancer: Peering behind the iron curtain. Pediatr Blood Cancer 2011; 56: 908.
14. Reddy K, Eng J, Carlson C, Ginsberg J, Fish J. Iron overload in childhood cancer survivors. 12th International Conference on Long- Term Complications of Treatment of Children and Adolescents for Cancer. Williamsburg, Virginia: St. Jude Children's Research Hospital and the National Cancer Institute; 2012. p. 25.
15. Ruccione KS, Mudambi K, Sposto R, Fridey J, Ghazarossian S, Freyer DR. Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. Pediatr Blood Cancer 2012; 59: 697-702.
16. Vag T, Kentouche K, Krumbein I, Reichenbach JR, Lopatta E, Renz DM, et al. Noninvasive measurement of liver iron concentration at MRI in children with acute leukemia: initial results. Pediatr Radiol 2011.
17. de Ville de Goyet M, Moniotte S, Robert A, Dupont S, Vermylen C, Veyckemans F, et al. Iron overload in children undergoing cancer treatments. Pediatr Blood Cancer 2013; 60: 1982-7.
18. Amid A, Barrowman N, Vijenthira A, Lesser P, Mandel K, Ramphal R. Risk factors for hyperferritinemia secondary to red blood cell transfusions in pediatric cancer patients. Pediatr Blood Cancer 2013; 60: 1671-5.
19. WoodJC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007; 14: 183-90.
20. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: 1460-5.
21. Kazak AE, Hocking MC, Ittenbach RF, Meadows AT, Hobbie W, DeRosa BW, et al. A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer 2012; 59: 96-9.
22. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328-43.
23. Wood JC. Personal communication 2013.
24. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009; 114: 4021-6.
25. Bonkovsky HL. Iron and the liver. Am J Med Sci 1991; 301: 32-43.
26. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003; 533: 153-71.
27. Lauret E, Rodriguez M, Gonzalez S, Linares A, Lopez-Vazquez A, Martinez-Borra J, et al. HFE gene mutations in alcoholic and virusrelated cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 1016-21.
28. Reitman A, Zomordian T, Ko R, Ruccione K, Coates T, Freyer D. Significant cardiac iron overload in an 11-year-old child with acute lymphoblastic leukemia (ALL) after only one year of treatment. ASPHO Abstracts. Pediatric Blood & Cancer 2014; 58: 1055.
29. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012; 366: 348-59.
30. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program 2009: 215-21.
31. Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program 2011; 2011: 443-50.
32. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, et al. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer 2012; 118: 1130-7.
33. Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A, et al. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 252-7.
34. Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005; 44: 220-5.
35. Arico M, Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R, et al. Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 2003; 88: 747-53.
36. Levine J. Fertility preservation in children and adolescents with cancer. Minerva pediatrica 2011; 63: 49-59.
37. Anderson B. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatr Blood Cancer 2005; 44: 584-8.